AirNexis Therapeutics develops clinical-stage therapies for chronic obstructive pulmonary disease and other pulmonary conditions.
AirNexis Therapeutics has raised $200.0M in total funding. The most recent round was Series A. The last funding was announced in January 2026.
AirNexis Therapeutics's investors include OrbiMed, Frazier Life Sciences, SR One, Longitude Capital, Enavate Sciences.
AirNexis Therapeutics is headquartered in Palo Alto, United States.
AirNexis Therapeutics develops clinical-stage therapies for chronic obstructive pulmonary disease and other pulmonary conditions.
AirNexis Therapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"AirNexis Therapeutics — Funding & Investors." VCBacked, January 9, 2026, https://www.vcbacked.co/company/airnexis-therapeutics. Accessed October 29, 2026.
VCBacked. (2026). AirNexis Therapeutics — Funding & Investors. Retrieved October 29, 2026, from https://www.vcbacked.co/company/airnexis-therapeutics
{{cite web |title=AirNexis Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/airnexis-therapeutics |website=VCBacked |access-date=October 29, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated